NATCO Pharma has launched generic Pomalidomide capsules in the US. This drug treats blood and bone marrow cancer. It is a generic version of Celgene's Pomalyst. The launch is in partnership with Breckenridge Pharmaceutical. This move aims to make specialty medicines accessible. It offers an affordable solution for patients.
[Image of multiple myeloma cancer cells in bone marrow]Product Details and Strategic Partnerships
Pomalidomide capsule is a generic version of Pomalyst by Celgene. The product is available in 1mg, 2mg, 3mg, and 4mg strengths and is distributed primarily through special channels.
"...this further strengthens our oncology and specialty portfolio in the US. The launch highlights our commitment to our mission of making specialty medicines accessible to all the patients worldwide. We look forward to bringing more such complex and specialty products to the market in the coming years."
Vice Chairman and CEO, NATCO Pharma
"Breckenridge's launch of Pomalidomide capsules delivers a high-quality, affordable generic solution, supported by copay assistance for eligible patients to help reduce treatment delays and ensure continuity of care."
President and Chief Commercial Officer, Breckenridge Pharmaceutical, Inc.
Medical Indications
Approved Uses for Pomalidomide Capsules:
- Multiple Myeloma: NATCO Pharma said Pomalidomide capsules are indicated for treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
- Kaposi Sarcoma: It is also approved for AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma, the company added.
